Dear Shareholders,As we look toward a promising and exciting year ahead, I am proud to reflect on CollPlant's main achievements throughout 2023. We leveraged our pioneering collagen-based platform and dynamic workforce
Companies Reporting Before The Bell
• CollPlant Biotechnologies (NASDAQ:CLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million.
Gainers
Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.